Salt Lake City, UT. , May 08, 2018 -- Utah Medical Products, Inc. (Nasdaq: UTMD) announces that its Board of Directors approved a quarterly cash dividend of twenty-seven cents ($.27) per share of common stock payable on July 6, 2018 to shareholders of record at the close of business on June 15, 2018. This is a 2% increase over the dividend declared in the same quarter of the prior year.
Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal long term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD’s website at www.utahmed.com.
Contact: Utah Medical Products, Inc. Crystal Rios (801) 566-1200


Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 



